MediWound (MDWD) to Release Quarterly Earnings on Wednesday

MediWound (NASDAQ:MDWD) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 21st. Analysts expect MediWound to post earnings of ($0.65) per share and revenue of $5.20 million for the quarter.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.23. The firm had revenue of $5.84 million for the quarter, compared to analysts’ expectations of $5.79 million. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same period in the previous year, the company posted ($0.19) earnings per share. On average, analysts expect MediWound to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MediWound Stock Up 2.5%

Shares of MDWD stock opened at $20.48 on Monday. The stock has a market cap of $221.35 million, a price-to-earnings ratio of -7.06 and a beta of 0.30. MediWound has a fifty-two week low of $12.78 and a fifty-two week high of $24.00. The firm’s 50 day moving average price is $17.28 and its two-hundred day moving average price is $17.54.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. StockNews.com raised shares of MediWound to a “sell” rating in a research report on Friday, March 21st. HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of MediWound in a research report on Thursday, March 20th. Alliance Global Partners started coverage on shares of MediWound in a research report on Friday, May 2nd. They set a “buy” rating and a $25.00 target price on the stock. Finally, Craig Hallum started coverage on shares of MediWound in a research report on Friday, February 28th. They set a “buy” rating and a $39.00 target price on the stock. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $29.75.

Institutional Trading of MediWound

An institutional investor recently raised its position in MediWound stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of MediWound Ltd. (NASDAQ:MDWD) by 22.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,452 shares of the biopharmaceutical company’s stock after purchasing an additional 999 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.05% of MediWound worth $85,000 as of its most recent SEC filing. Institutional investors and hedge funds own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.